Abstract
BACKGROUND AND PURPOSE: Antiplatelet drug resistance has been associated with thromboembolic complications in patients after coronary stent placement. It has not been well-studied in patients who have neurovascular stent-placement procedures. This study aimed to analyze the relationship between antiplatelet drug resistance and neurovascular stent-placement complications.
MATERIALS AND METHODS: A prospective data base of all patients treated at our institution was used to identify patients with neurovascular stent-placement procedures. During a 4.5-year period, all patients undergoing neurovascular stent placement were evaluated for aspirin and clopidogrel resistance by using the VerifyNow assay. During an observational phase, all patients received 75 mg of clopidogrel and aspirin (group A). During the intervention phase (group B), patients were given additional clopidogrel on the basis of the clopidogrel resistance assay. We assessed the development of thromboembolic complications within 30 days of the procedure in patients who were resistant-versus-nonresistant to clopidogrel.
RESULTS: Of 96 patients who had neurovascular stent placement, 5.2% were resistant to aspirin and 36.5% were resistant to clopidogrel. Periprocedural thromboembolic complications were seen in 7 patients (7.3%). In a multivariate logistic regression model, clopidogrel resistance, higher diastolic blood pressure, and lack of statin use were significantly associated with periprocedural thromboembolic complication. There was a nonsignificant decrease in thromboembolic complications in patients whose clopidogrel dosage was tailored to the assay.
CONCLUSIONS: In our series, clopidogrel resistance was associated with increased periprocedural thromboembolic complications from neurovascular stent-placement procedures. Targeting the clopidogrel dose to platelet inhibition assays may improve clinical outcomes and requires further study.
ABBREVIATIONS:
- ACT
- activated clotting time
- ARU
- aspirin reaction units
- LTA
- light transmittance aggregometry
- PCI
- percutaneous cardiovascular interventions
- PRU
- P2Y12 reaction units
- © 2013 by American Journal of Neuroradiology
In this issue
Jump to section
Related Articles
Cited By...
- Prasugrel Single Antiplatelet Therapy versus Aspirin and Clopidogrel Dual Antiplatelet Therapy for Flow Diverter Treatment for Cerebral Aneurysms: A Retrospective Multicenter Study
- Short- versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE): a multicenter, open-label, randomized clinical trial
- Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update
- Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment
- Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update
- Short- versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE): a multicenter, open-label, randomized clinical trial
- Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives
- Ticagrelor versus Clopidogrel in the Dual Antiplatelet Regimen for Intracranial Stenting or Flow-Diverter Treatment for Unruptured Cerebral Aneurysms: A Single-Center Cohort Study
- Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience
- Dose adjustment of clopidogrel in hyper-responder patients with unruptured intracranial aneurysms treated with stents
- The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease
- Relationship between adverse events and antiplatelet drug resistance in neurovascular intervention: a meta-analysis
- Contribution of whole platelet aggregometry to the endovascular management of unruptured aneurysms: an institutional experience
- Association of thrombelastographic parameters with post-stenting ischemic events
- Treatment of Intra- and Extracranial Aneurysms Using the Flow-Redirection Endoluminal Device: Multicenter Experience and Follow-Up Results
- Intraprocedural abciximab bolus versus pretreatment oral dual antiplatelet medication for endovascular stenting of unruptured intracranial aneurysms
- Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms
- Retrospective Analysis of Delayed Intraparenchymal Hemorrhage after Flow-Diverter Treatment: Presentation of a Retrospective Multicenter Trial
- Flow diverter device for the treatment of small middle cerebral artery aneurysms
- Platelet Testing is Associated with Worse Clinical Outcomes for Patients Treated with the Pipeline Embolization Device
- Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate
- Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device
- Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation
- Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms
- Platelet function inhibitors and platelet function testing in neurointerventional procedures
- Thromboembolic Complications in Patients with Clopidogrel Resistance after Coil Embolization for Unruptured Intracranial Aneurysms
- Antiplatelet testing in neurointervention: we cannot ignore the signs
- Platelet-Function Testing in Patients Undergoing Neurovascular Procedures: Caught between a Rock and a Hard Place